Abstract: Methods of treating inflammatory conditions, disease and disorders of skin are provided. Methods include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat skin inflammation, skin fibrosis, or a skin fibrotic disease or disorder such as scleroderma, atopic dermatitis, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, keloid, sclerodactyly, or eosinophilic fasciitis.

Abstract: The present application relates to composition of matter, processes and use of composition of matter relating to flavivirus peptides and epitopes, for example, for therapeutic or preventative vaccination against a flavivirus, and/or for inducing, enhancing, or sustaining an immune response against a flavivirus, and/or for detecting an infection with or an exposure to a flavivirus in a subject. The flavivirus may be for example the Zika and/or Dengue virus.

Abstract: The present disclosure relates to methods and compositions useful for initiating and propagating ICOS-mediated signaling. In particular, the present disclosure provides three peptide motifs which promote ICOS binding and whose ablation leads to modulated ICOS signaling and modulated signaling mediated by TBK1, IRF4, IKK?, or TBKBP1. The binding of these peptide motifs or the addition of such motifs as co-stimulatory agents leads to modulated immune responses, and provides new and unexpected therapies for neurodegenerative, autoimmune, metabolic, cancer inflammatory, or immunodeficiency conditions, diseases, or disorders.

Abstract: The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.

Abstract: Methods are disclosed for identifying whether a subject is likely to respond to a therapy for treatment of an allergy (e.g., a food allergy or an allergic reaction), hypersensitivity, asthma, inflammatory response or inflammation by detecting the level of an HRF monomer, an HRF dimer, an HRF multimer, or an HRF-reactive Ig molecule in a sample isolated from the subject. Also provided are methods for diagnosing or determining the severity of a condition selected from an allergy (e.g., a food allergy or an allergic reaction), hypersensitivity, asthma, inflammatory response or inflammation/or severity of allergic reaction, or inflammation in a subject. Treatments for allergic conditions are further provided herein, as well as kits for the diagnosis, monitoring and treatment of the conditions.

Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+ GR1? (Ly6C?)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.

Abstract: This disclosure provides agents that are useful for modulating an immune response in subject and for treating diseases, such as autoimmune diseases, cardiovascular diseases, infectious diseases, and cancer. These agents may comprise an olfactory receptor (OLFR), an OLFR ligand, or a protein involved in the trafficking of an OLFR to the plasma membrane of a cell. Alternatively, the agents may modulate the expression or activity of an OLFR, OLFR ligand, or protein involved in the trafficking of the OLFR to the plasma membrane of a cell.

Abstract: The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cells alone or in combination with each other and/or additional therapies.

Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Abstract: This disclosure provides methods of treating cancer or eliciting an anti-tumor response in a subject by administering an effective amount of a population of T-cells that exhibits higher or lower than baseline expression of one or more genes. In other aspects, methods are provided to diagnose cancer and determine prognosis of cancer patients. Also provided are methods to identify the antigens or antigen receptors associated with the isolated and/or purified cell populations that elicit a more positive prognosis.

Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.

Abstract: The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologs, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.

Abstract: The present disclosure relates to methods and compositions useful for initiating and propagating ICOS-mediated signaling. In particular, the present disclosure provides three peptide motifs which promote ICOS binding and whose ablation leads to modulated ICOS signaling and modulated signaling mediated by TBK1, IRF4, IKK?, or TBKBP1. The binding of these peptide motifs or the addition of such motifs as co-stimulatory agents leads to modulated immune responses, and provides new and unexpected therapies for neurodegenerative, autoimmune, metabolic, cancer inflammatory, or immunodeficiency conditions, diseases, or disorders.

Abstract: The invention relates to compositions, methods and uses of inhibitors of binding between PKC? and CD28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between PKC? and CD28, which include, among others, PKC?, CD28 and Lck sequences, subsequences, variants and modified forms, and polymorphisms.

Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes; CD14+CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or sub-sequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+CD16+ monocytes and/or CD14dimCD16+(CD115+CD11b+GR1?(Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.

Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.

Abstract: The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.

Abstract: Method and compositions for modulating specific populations of monocytes or macrophages are disclosed. Methods include, in certain embodiments, modulating expression or activity of Nr4a1 (Nur77). Compositions disclosed herein include agonistic and antagonistic agents that modulate expression or activity of Nur77 and uses thereof. In various embodiments, methods of treating certain disorders and diseases related to aberrant monocyte or macrophage development are provided. In further various embodiments, methods of identifying agents that modulate specific populations of monocytes or macrophages, and agents that modulate Nur77 activity and/or expression are provided.

Abstract: Presented herein are methods of detecting and/or monitoring germinal center activity in a subject according to an amount of CXCL13 in the blood of a subject. Also presented herein are methods of determine the efficacy of a vaccine or antigen at inducing an immune response. Methods are also presented for monitoring, screening, and/or diagnosing an autoimmune disorder or immune-suppression in a subject and for monitoring or adjusting a treatment.